Distribution of human papilloma virus genotypes in cancerous lesions of cervix: Insights from a hospital-based study in Bangladesh Authors: Shirin Akter Begum, Tasfia Mahmud, Mehriban Amatullah, Ashrafun Nessa Published: 2026 ABSTRACT BACKGROUND:Persistent infection with high-risk human papillomavirus is a primary contributor to the development of cervical precancerous lesions and cervical malignancy. Understanding the hrHPV genotype prevalence is essential for guiding vaccination and screening strategies. This study was done to determine the prevalence of high-risk HPV genotypes in women with histopathologically confirmed cervical cancer and precancerous cervical lesions.MATERIALS AND METHODS:This was a descriptive cross-sectional study conducted at the Colposcopy Clinic in the Department of Gynecologic Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, between August 2022 and July 2024. A total of 300 women aged 25 years or older with histologically confirmed cervical lesions (125 with CIN and 175 with invasive cervical cancer) were enrolled.RESULTS:Among 175 invasive cervical cancer cases, 152 (86.9%) were hrHPV-positive. HPV-16 was the most common genotype, detected in 104 (68.4%) of hrHPV-positive cases as a single infection and 116 (76.3%) as a dominant type in multiple infections. Other notable genotypes included HPV-18 (4.6%), HPV-39 (3.3%), and HPV-35, 52, and 59 (each 2.6%). HPV types 45, 66, and 68 were among the less commonly identified high-risk genotypes, each accounting for 3 (2.0%) of cases. Multiple hrHPV infections were observed in 17.1% of cancer cases. Histologically, squamous cell carcinoma was the predominant subtype in both HPV-positive and HPV-negative groups.CONCLUSION:The predominance of HPV-16 underscores the need to expand national HPV vaccination and screening programs, using genotype-specific data to guide policies aligned with the WHO’s cervical cancer elimination strategy. Introduction Cervical cancer remains one of the leading causes of cancer morbidity and mortality among women globally, particularly in low- and middle-income countries such as Bangladesh.[1] It is now well-established that persistent infection with high-risk human papillomavirus (hr-HPV) genotypes is a necessary etiological agent in the development of cervical intraepithelial neoplasia (CIN) and invasive cervical carcinoma.[2] Among more than 200 HPV genotypes known so far, approximately 14 are high-risk by their oncogenic potential, with HPV-16 and HPV-18 accounting for nearly 70% of all cervical cancer cases worldwide.[3] Cervical cancer remains a major health burden in Bangladesh, largely due to limited awareness, low screening coverage, and inadequate HPV vaccination uptake.[4] Most women present at an advanced stage of the disease, significantly limiting treatment options and survivability.[56789] Characterization of the distribution of hr-HPV genotypes in this population is therefore important for informing targeted preventive interventions. Also, the selection of HrHPV types for vaccine development and the design of genotype-specific screening tests are necessary.[6] Despite global advances, genotype-specific HPV prevalence among Bangladeshi women with histologically confirmed cervical lesions is scarce.[10] Moreover, the distribution of specific genotypes across different histological subtypes, such as squamous cell carcinoma (SCC) and adenocarcinoma, is insufficiently characterized in this population. Since these subtypes differ in their biological behavior and therapeutic approaches, genotype-specific profiling is crucial for effective disease control and vaccine policy development.[11] This hospital-based study attempted to address these gaps by determining the prevalence of high-risk HPV genotypes in women with histopathologically confirmed cervical cancer and precancerous cervical lesions. The findings derived from the study can potentially convey the message to policymakers to reschedule for genotype-specific screening, early detection, and HPV vaccination strategies in Bangladesh. The objective of this study was to determine the prevalence and distribution of high-risk HPV genotypes among Bangladeshi women with histologically confirmed cervical precancerous and cancerous lesions. Materials and Methods Study design and setting This descriptive cross-sectional study was conducted at the Colposcopy Clinic, Department of Gynecologic Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, over a two-year period from August 2022 to July 2024. The study aimed to describe the distribution of high-risk human papillomavirus (hrHPV) genotypes among women with histologically confirmed cervical intraepithelial neoplasia (CIN) and invasive cervical cancer. Study participants and sampling A total of 300 women aged 25 years or older, presenting to the Outpatient and Colposcopy Clinics of BSMMU, with histologically confirmed cervical lesions were enrolled. Of these, 125 cases had precancerous lesions (CIN1–CIN3) and 175 had invasive cervical cancer. Women with previous treatment for cervical cancer or concurrent gynecologic malignancies were excluded. Participants were selected consecutively after confirmation by histopathology. Only those with histologically confirmed CIN or cervical cancer and a valid HPV DNA test result were included. Data collection tool and technique Colposcopic examinations were performed on women who screened positive. The cervix was examined after application of 5% acetic acid and Lugol’s iodine, with vascular patterns observed under a green filter and standard light. The Swede score was used to evaluate colposcopic findings. Directed biopsies were taken from abnormal areas, and random biopsies from the transformation zone were collected if colposcopy appeared normal despite a positive screen. For cancer cases, biopsies were obtained directly from the tumor. Hemostasis was achieved using Monsel’s solution. Simultaneously, cervical samples were collected for HPV DNA testing in all screen-positive and cancer cases. Only histologically confirmed precancerous and cancerous lesions were retained for analysis; benign or inflammatory lesions were excluded. HPV DNA testing was performed using real-time polymerase chain reaction (PCR). Genotyping was conducted with the GenoFlow HPV Array Test, involving DNA extraction, PCR amplification, and hybridization with type-specific probes. Sequencing was used for confirmation. Sociodemographic (age, education, income) and clinical data were collected via a pretested semi-structured questionnaire administered by trained personnel. Ethical consideration Ethical approval for the study was obtained from the Institutional Review Board (IRB) of Bangabandhu Sheikh Mujib Medical University (BSMMU) (Approval No: BSMMU/2023/6523). Written informed consent was obtained from all participants following a detailed explanation of the study’s purpose and procedures. Statistical analysis method Data analysis was performed using SPSS version 25. Descriptive statistics were used to summarize the prevalence and distribution of hrHPV genotypes. The analysis also included the correlation between HPV status, genotype, and histopathological subtypes. Results Table 1 summarizes the demographic and clinical profiles of 300 participants. The majority were aged 3150 years (61.0%, n = 183), with a mean age of 46.85 ± 0.65 years. A significant proportion were illiterate Table 1Distribution of respondents by their demographic characteristics (n=300)CharacteristicsFrequencyPercentageAge (years) ≤30196.33 31–5018361.00 >509832.67Education Illiterate12541.67 Primary9531.67 SSC4314.33 HSC217.00 Graduate plus165.33Monthly Income (Taka) ≤10000 (Poor)17157.00 10000-25000 (Lower middle class)9431.33 26000-50000 (Middle class)227.33 >50000 (Solvent or Rich)134.33Histopathological Diagnosis Precancerous Lesions (CIN I–III, CIS)12541.70 Invasive Cancer17558.30*Mean age=46.85±0.648 years; range=(23–77) yrs Distribution of respondents by their demographic characteristics (n=300) *Mean age=46.85±0.648 years; range=(23–77) yrs (41.7%, n = 125), and over half (57.0%, n = 171) had a monthly income of ≤10,000 Taka, indicating low socioeconomic status. Histopathological analysis revealed that 58.3% (n = 175) had invasive cancer, while 41.7% (n = 125) showed precancerous lesions (CIN I-III) or carcinoma in situ (CIS). Table 2 shows high-risk HPV (hr-HPV) detection among 175 cervical cancer cases. A substantial majority of these cases was tested positive for hr-HPV DNA (86.9%, n = 152), while 13.1% (n = 23) were HPV negative. This confirms hr-HPV’s strong etiological role in cervical carcinogenesis, though the negative cases suggest alternative oncogenic pathways may exist. Table 2Distribution of HPV DNA Status in Cervical Cancer (n=175)HPV DNA StatusFrequencyPercentagePositive15286.9Negative2313.1 Distribution of HPV DNA Status in Cervical Cancer (n=175) Table 3 demonstrates the distribution of HPV infection across histological subtypes in 152 HPV-positive cervical cancers. Squamous cell carcinoma (SCC) was predominant (80.3%), while adenocarcinomas comprised 19.7% of the cases. Table 3Distribution of HPV-DNA positive cases in cancer by histological type (n=152)Histopathological SubtypeFrequencyPercentageSquamous Cell Carcinoma (SCC)12280.3Adenocarcinoma3019.7 Distribution of HPV-DNA positive cases in cancer by histological type (n=152) Table 4 describes the distribution of genotypes among HPV-positive cervical cancers. HPV-16 was detected as the most prevalent single infection (68.4%, n = 104), while HPV-18 accounted for only 4.6% (n = 7). Multiple genotypes were observed in 12.5% of cases (n = 19), with HPV-16-containing combinations being twice as common (7.9%) as (4.6%). Additionally, 11.2% (n = 17) of cases involved other single genotypes. Table 4HPV genotype distribution among HPV-positive cancer cases (n=152)HPV GenotypeFrequencyPercentageHPV-1610468.4HPV-1874.6HPV-3953.3Multiple genotypes with HPV-16 predominant127.9Multiple genotypes without HPV-1674.6Other single genotypes1711.2 HPV genotype distribution among HPV-positive cancer cases (n=152) Table 5 demonstrates the distribution of high-risk HPV genotypes among 152 HPV-positive cervical cancer cases, revealing HPV-16 as the overwhelmingly dominant genotype, present in 76.3% of cases either as single infections or dominant multiple infections. While HPV-18 was identified in 4.6% of cases, other significant genotypes included HPV-39 (3.3%), HPV-35, HPV-52, and HPV-59 (2.6%). Less frequently encountered but still clinically relevant genotypes were HPV-66, HPV-68, and HPV-45 (2.0% each), followed by HPV-31 and HPV-56 (1.3% each). Notably rare genotypes included HPV-33, HPV-58, and HPV-51, each appearing in just 0.7% of cases. Table 5High-risk HPV genotypes among HPV-positive cancer cases (n=152)High-Risk HPV GenotypeFrequencyPercentageHPV-16 + HPV-16 dominant multiples11676.3HPV-1874.6HPV-3953.3HPV-3542.6HPV-5242.6HPV-5942.6HPV-6632.0HPV-6832.0HPV-4532.0HPV-3121.3HPV-5621.3HPV-3310.7HPV-5810.7HPV-5110.7 High-risk HPV genotypes among HPV-positive cancer cases (n=152) Table 6 presents the histological subtypes of 23 HPV-negative cervical cancer cases, squamous cell carcinoma (SCC) accounted for majority (78.3%, n = 18) of the cases, while adenocarcinomas represented 21.7% only. Table 6Distribution of HPV-negative cancer cases by histological type (n=23)Histopathological SubtypeFrequencyPercentageSquamous Cell Carcinoma (SCC)1878.3Adenocarcinoma521.7 Distribution of HPV-negative cancer cases by histological type (n=23) Discussion This hospital-based study provides important insights into the prevalence of high-risk HPV (hrHPV) genotypes among Bangladeshi women with histologically confirmed cervical cancer. Our findings show a high burden of hrHPV, with 86.9% of invasive cervical cancer cases testing positive for hrHPV DNA, while 13.1% were HPV-negative. Squamous cell carcinoma (SCC) was the most common histological type in both HPV-positive (80.3%) and HPV-negative (78.3%) cases. These results are consistent with global data from de Sanjosé et al.,[5] who detected HPV DNA in 85% of 10,575 invasive cervical cancer cases worldwide, with HPV-16 and HPV-18 accounting for 71% of HPV-positive cases, and 15% of cases testing HPV-negative.[12] This study found that HPV-16 was the most prevalent genotype (68.4%). When including cases where HPV-16 co-occurred with other hrHPV types, its presence increased to 76.3%, underscoring its dominant role. This prevalence exceeds earlier reports from Bangladesh by Jahan et al. and Saha et al., but is consistent with international studies, including those by Liu et al. in China and Wolday et al. in Ethiopia, where HPV-16 was also the most common oncogenic type.[13141516] In contrast, HPV-18 was found in only 4.6% of cases in this study, which is lower than the rates reported in regions like Africa, Asia, Europe, the Americas, and Oceania. This variation may be due to regional differences in HPV genotype distribution. For context, de Sanjosé et al. reported a global prevalence of HPV-18 in about 10% of cervical cancer cases.[12] Besides HPV-16 and HPV-18, other hrHPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, were also identified in the present study. While these genotypes were less common, their presence in invasive cancer cases supports by other studies, who also highlighted the significant contribution of non-16/18 hrHPV types to cervical cancer. These types could reduce the effectiveness of vaccines that don’t include them, emphasizing the need for broader vaccine coverage.[1718] Co-infections without HPV-16 accounted for only 23.7%. These rates are consistent with global estimates, where HPV-16 is responsible for 50–60% of cervical cancer cases, and multiple hrHPV infections occur in about 22–25% of hrHPV-positive cases. Although the clinical significance of multiple infections remains debated, co-infections may enhance persistent oncogenic activity, although the clinical significance of multiple infections remains debated.[19] However, Sharmin et al.[20] found no association between lesion severity and non-16/18 genotypes among Bangladeshi women. Interestingly, 13.1% of invasive cervical cancer cases in our study were HPV-negative, suggesting that some cervical cancers may arise through HPV-independent pathways. Different hrHPV genotypes vary in their carcinogenic potential, and this variation may influence cancer development. Our findings align with those of Stuebs et al.,[21] who reported 10.5% HPV-negative cases in their cohort. Their study also noted a distinct genotype distribution, with non-16/18 genotypes more frequently associated with non-squamous histologies and higher-grade lesions. These findings underscore the importance of further research into HPV-negative cervical carcinogenesis, which could play a crucial role in achieving the WHO’s goal of eliminating cervical cancer by 2030. Lastly, the high prevalence of HPV-16 (68.4%) and HPV-18 (4.6%), together accounting for around 73% of cases, supports the continued use of bivalent and quadrivalent vaccines in Bangladesh. The detection of other high-risk HPV types like HPV-39 (3.3%), HPV-45 (2.0%), and HPV-33 (0.7%) underscores the potential advantage of adopting the nonavalent vaccine for more comprehensive protection. As Zhang et al.[22] emphasized, continuous regional monitoring of HPV genotypes is essential to guide effective vaccination and screening strategies that reflect local epidemiological trends. This study has several limitations. Its cross-sectional design prevents assessment of HPV persistence or progression over time. Being hospital-based, there is a potential for selection bias, as the findings may not fully represent the general population. Additionally, the absence of data on immune status or behavioral risk factors may have influenced genotype distribution. Despite these limitations, the study’s strengths include the use of histologically confirmed cases, standardized colposcopic evaluation, and reliable PCR-based genotyping, providing robust insights into hrHPV distribution in a high-risk population. Limitations of the study This study was limited by its relatively small sample size and hospital-based single-center design, which may affect generalizability to a cross-section of the population. Additionally, only women with histologically confirmed lesions were analyzed, potentially overlooking early HPV infections. Suggestions for further research Future studies should explore the natural history and persistence of specific hrHPV genotypes through longitudinal designs. Multicenter, population-based studies are also needed to overcome selection bias and improve generalizability. Additionally, evaluating the molecular mechanisms of HPV-negative cervical cancers and the host immune response to multiple infections would provide deeper insights into cervical carcinogenesis in diverse populations. Conclusion In conclusion, this study reaffirms the central role of HPV-16 in cervical cancer in Bangladesh and highlights the presence of other oncogenic hrHPV types. Wide range of vaccine coverage and genotypes informed screening and vaccination protocols are essential for comprehensive cervical cancer prevention in this region. As HPV-16 is the most common type of hrHPV in cervical cancer lesions. So it is very important to keep on surveillance of those women diagnosed with CIN 3/HSIL who are aged ≤ 35 and is decreasing with age. Therefore, women age ≥ 35 with persistent infection with hrHPV 16 need careful evaluation and monitoring, as because it leads to cervical cancer. AI policy statement In accordance with journal policy, we disclose that OpenAI’s ChatGPT was used as a language support tool in drafting and refining the manuscript, particularly in improving clarity, grammar, and structure. No data analysis, image generation, or interpretation of results was performed by the AI tool. The authors remain fully responsible for the integrity, originality, and ethical compliance of all manuscript content, including sections supported by AI. Abbreviations hrHPV: High-risk human papillomavirus; CIN: Cervical intraepithelial neoplasia; BSMMU: Bangabandhu Sheikh Mujib Medical University; PCR: Polymerase chain reaction; SCC: Squamous cell carcinoma. Conflicts of interest There are no conflicts of interest.